Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IGM-7354 · 1 trial · 1 indication
Incidence of treatment-emergent AEs, SAEs, and DLT per NCI CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| IGM-7354 Single-Agent Dose Escalation | EXPERIMENTAL | IGM-7354 will be administered intravenously as a single agent. |
| IGM-7354 Single-Agent Dose Expansion Serial Biopsy | EXPERIMENTAL | IGM-7354 will be administered intravenously as a single agent and patients will undergo pre-treatment and on-treatment biopsies. |
| Name | Type | Description |
|---|---|---|
| IGM-7354 | DRUG | IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects |
Key Inclusion Criteria: * Age \> 18 years at time of signing ICF * ECOG Performance Status of 0 or 1 * Histologic or cytologic documentation of incurable, locally advanced or metastatic solid tumors for which standard therapies are not available, are no longer effective, are not tolerated, or have ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IGM-7354 is an investigational therapy being studied for the treatment of solid tumors. It is being developed for adults with relapsed and/or refractory cancer, meaning disease that has returned or has not responded to prior treatment. It has not been approved for any use and remains in clinical development.
IGM-7354 targets PD-L1, a protein that tumors use to suppress immune responses. By binding PD-L1, the drug is designed to interfere with that immune-evasion pathway in solid tumors. IGM-7354 is a small molecule directed at PD-L1 and is being evaluated in oncology.
IGM-7354 is being developed by IGM Biosciences, Inc., which trades on the Nasdaq under the ticker IGMS. The company is the sponsor of the clinical program evaluating the agent in patients with relapsed and/or refractory solid tumors.
IGM-7354 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory authority. The Phase 1 program has been conducted in adults with relapsed and/or refractory cancer.
IGM-7354 has been evaluated in one Phase 1 clinical trial, NCT05702424, titled Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer. That study enrolled 14 participants with solid tumors in the United States and is listed as completed. It was a controlled study that enrolled adults aged 18 years and older.